NewcelX Appoints Dr. Julien Boisdron to Advisory Board
NewcelX AG's stock surged by 14.61% in pre-market trading as it crossed above the 5-day SMA, reflecting positive investor sentiment.
The company has appointed Dr. Julien Boisdron, a diabetes expert, to its Scientific Advisory Board. His extensive experience in diabetes treatment will provide strategic guidance for NewcelX's IsletRx program, which focuses on developing stem-cell-derived islet cell therapy for Type 1 Diabetes. This appointment is expected to enhance the company's competitiveness and advance its clinical trial processes.
Dr. Boisdron's involvement is anticipated to strengthen NewcelX's strategic direction in cell therapy, facilitating the global commercialization of innovative treatments. His expertise will help integrate patient needs with health system requirements, positioning NewcelX favorably in the metabolic and regenerative medicine landscape.
Analyst Views on NCEL
About NCEL
About the author






